Indivior PLC (the
'Company')
Result of General Meeting
May
23, 2024
The Company announces the voting
result of its General Meeting, held earlier today at the
offices of Freshfields Bruckhaus Deringer, 100 Bishopsgate, London
EC2P 2SR.
The resolution set out in the Notice
of Meeting circulated to shareholders and published on May 3, 2024
was duly passed by shareholders by way of a poll.
The voting result, incorporating proxy votes lodged
in advance of the General Meeting, is set out below and will be
made available on the Company's website at http://www.indivior.com/en/investors/shareholder-information.
RESOLUTION
|
VOTES
FOR
|
%
|
VOTES
AGAINST
|
%
|
VOTES
TOTAL
|
% of ISC
VOTED1
|
VOTES
WITHHELD2
|
To approve the transfer of the
Company's category of equity share listing on the London Stock
Exchange plc from a Premium Listing to a Standard
Listing
|
86,261,468
|
96.94
|
2,718,492
|
3.06%
|
88,979,960
|
65.86
|
9,491
|
Graham Hetherington, Chair, said:
'We
are pleased with the strong support received from shareholders at
today's General Meeting to enable Indivior to move its primary
listing to the Nasdaq Stock Market. We believe that this move will
better align with the Group's current and future growth
opportunities, attract more U.S. investors and analysts, allow for
inclusion in U.S. indices over time and better reflect the growing
proportion of our investors that are based in the
U.S.
We
expect the transfer of the primary listing will become effective on
Thursday June 27, 2024. The Board intends to maintain Indivior's
U.K. listing as a secondary listing following the
transfer for as long as it is
considered to be in the best interests of Indivior and Indivior
shareholders as a whole.'
Notes:
1. As at the
close of business on May 21, 2024, the total number of
ordinary shares of US$0.50 eligible to be voted at the GM was
135,096,376. Therefore, the total voting rights in the
Company as at that time was 135,096,376.
2. A vote
withheld is not a vote in law and is not counted in the calculation
of the votes for or against a resolution.
A copy of the resolution will be
submitted to the National Storage Mechanism and will be available
to view at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
in due course.
Computershare Investor Services PLC
acted as scrutineer of the poll on the resolution.
Key Contacts:
Jason Thompson
VP, Investor Relations
+1 804-402-7123
or jason.thompson@indivior.com
Tim Owens
Director, Investor
Relations
+1 804-263-3978
or timothy.owens@indivior.com
Kathryn Hudson
Company Secretary
+44 (0)1753 423940
or kathryn.hudson@indivior.com
About Indivior
Indivior is a global pharmaceutical
company working to help change patients' lives by developing
medicines to treat substance use disorders (SUD) and serious mental
illnesses. Our vision is that all patients around the world will
have access to evidence-based treatment for the chronic conditions
and co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD,
including alcohol use disorder and cannabis use disorder.
Headquartered in the United States in Richmond, VA, Indivior
employs over 1,100 individuals globally and its portfolio of
products is available in 37 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/
company/indivior.
Important Cautionary Note
Regarding Forward-Looking Statements
This announcement contains certain statements that are forward-looking.
Forward-looking statements include, among other things, statements
regarding our intention to transfer our primary listing to Nasdaq
while maintaining a secondary listing in the U.K., and the expected
timing and potential benefits of such transfer; expected future
growth; and other statements containing the words "believe,"
"anticipate," "plan," "expect," "intend," "estimate," "forecast,"
"strategy," "target," "guidance," "outlook," "potential,"
"project," "priority," "may," "will," "should," "would," "could,"
"can," "outlook," "guidance," the negatives thereof, and variations
thereon and similar expressions. By their nature, forward-looking
statements involve risks and uncertainties as they relate to events
or circumstances that may or may not occur in the
future.
Actual results may differ materially
from those expressed or implied in such statements because they
relate to future events. Various factors may cause differences
between Indivior's expectations and actual results, including,
among others, the material risks described in the most recent
Indivior PLC Annual Report and in subsequent releases; the
substantial litigation and ongoing investigations to which we are
or may become a party; our reliance on third parties to manufacture
commercial supplies of most of our products, conduct our clinical
trials and at times to collaborate on products in our pipeline; our
ability to comply with legal and regulatory settlements, healthcare
laws and regulations, requirements imposed by regulatory agencies
and payment and reporting obligations under government pricing
programs; risks related to the manufacture and distribution of our
products, most of which contain controlled substances; market
acceptance of our products as well as our ability to commercialize
our products and compete with other market participants;
competition; the uncertainties related to the development of new
products, including through acquisitions, and the related
regulatory approval process; our dependence on third-party payors
for the reimbursement of our products and the increasing focus on
pricing and competition in our industry; unintended side effects
caused by the clinical study or commercial use of our products; our
ability to successfully execute acquisitions, partnerships, joint
ventures, dispositions or other strategic acquisitions; our ability
to protect our intellectual property rights and the substantial
cost of litigation or other proceedings related to intellectual
property rights; the risks related to product liability claims or
product recalls; the significant amount of laws and regulations
that we are subject to, including due to the international nature
of our business; macroeconomic trends and other global developments
such as armed conflicts and pandemics; the terms of our debt
instruments, changes in our credit ratings and our ability to
service our indebtedness and other obligations as they come due;
changes in applicable tax rate or tax rules, regulations or
interpretations and our ability to realize our deferred tax assets;
and volatility in our share price due to factors unrelated to our
operating performance or that may result from the potential move of
our primary listing to the U.S.
Forward-looking statements speak
only as of the date that they are made and should be regarded
solely as our current plans, estimates and beliefs. Except as
required by law, we do not undertake and specifically decline any
obligation to update, republish or revise forward-looking
statements to reflect future events or circumstances or to reflect
the occurrences of unanticipated events.
Indivior PLC's Legal Entity
Identifier code is 213800V3NCQTY7IED471.